Phase 2 N=34 Pilot of Zinc Acetate to Improve Chronic Cough
Cough
Primary: Change in Cough Quality of Life Questionnaire (CQLQ) Score by Treatment Group — -5.00; -6.00 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
Phase 2 N=18 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas
Phase 2 N=4 A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
PNH
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 3; 2; 1; 0 Participants
Phase 2 N=403 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Schizophrenia
Primary: Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total Score — 61.8; 61.0; -10.5; -8.8 score on a scale — p=0.0434
Phase 2 N=17 Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Medullary Thyroid Carcinoma · Multiple Endocrine Neoplasia Type 2A · Multiple Endocrine Neoplasia Type 2B
Primary: Maximum Tolerated Dose (MTD) — 100 mg/m^2/day
Phase 2 N=151 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
Presbyopia
Primary: Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters in the Nondominant Eye — 3.00; 4.96; 7.77; 7.54 letters correctly read — p=0.1663
Phase 2 N=163 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
Presbyopia
Primary: Weighted Average Change From Baseline in Mesopic, High Contrast Uncorrected Near Visual Acuity (UNVA) Letters — 1.12; 3.83; 5.26; 5.42 letters correctly read — p=0.0029
Phase 2 N=225 Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Prostate Cancer
Primary: Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases — .59; .89 proportion of participants
Phase 2 N=31 Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection
Hepatitis B · Chronic Hepatitis B Atypical
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%) — 5; 6; 2; 3 Participants
Phase 2 N=90 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
Stage I Papillary Thyroid Cancer · Stage II Papillary Thyroid Cancer · Stage III Papillary Thyroid Cancer
Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…
Phase 2 N=122 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Phase 2 N=89 Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ulcerative Colitis · Crohn's Disease
Primary: AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14 — 1933.5076; 3231.1001; 2344.4204; 3091.7957 h*ng/mL
Phase 2 N=40 Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB
HIV Infections · Tuberculosis
Primary: Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir…
Phase 2 N=141 Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Breast Neoplasms
Primary: Progression Free Survival (PFS) — 3.5; 7.2; 5.6 months — p=0.537